Trials / Not Yet Recruiting
Not Yet RecruitingNCT05912582
Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Jiangsu Cancer Institute & Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This clinical research aims to explore potential biomarkers and validate molecular signatures' predictive and prognostic value in nasopharyngeal carcinoma.
Detailed description
Primary endpoint: Evaluation of the major pathological response of nasopharyngeal carcinoma patients. Secondary endpoint: Evaluation of failure-free survival and overall survival of nasopharyngeal carcinoma patients. Outline: This is a prospective observational study. Patients of nasopharyngeal carcinoma undergo inductive chemotherapy and concurrent chemoradiotherapy. Whole blood is obtained from patients when recruited, completing 10, 20, 32 fractions of radiation therapy, 3 months after radiation therapy and disease progression. Tumor tissue specimens are obtained from patients when recruited and disease progression. The samples are analyzed for biomarkers and spatial transcriptomics. The biomarkers and spatial transcriptomics are correlated with clinical outcomes (major pathological response, progression-free survival, overall survival, tumor response to treatment, distant metastasis, recurrence and death). The analysis aims to explore potential biomarkers and validate molecular signatures' predictive and prognostic value in nasopharyngeal carcinoma. This will lead to the definition of risk groups and stratification of patients and will help in precision medicine of nasopharyngeal carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Intensity modulated radiation therapy (IMRT) combined with chemotherapy | Intensity modulated radiation therapy (IMRT) combined with chemotherapy |
Timeline
- Start date
- 2025-12-25
- Primary completion
- 2027-06-25
- Completion
- 2028-12-25
- First posted
- 2023-06-22
- Last updated
- 2025-12-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05912582. Inclusion in this directory is not an endorsement.